Ma-Spore ALL 2020 Study

This study (Ma-Spore ALL 2020) is evaluating a treatment protocol for B-cell acute lymphoblastic leukemia (ALL) — a cancer of the white blood cells — in children, adolescents, and young adults across Malaysia and Singapore. The goal is to improve treatment outcomes using a risk-adapted approach. **You may be eligible if...** - You are under 41 years old - You have been newly diagnosed with B-cell acute lymphoblastic leukemia (B-ALL), confirmed by bone marrow testing and cell typing - You (or your legal guardian) have provided written informed consent **You may NOT be eligible if...** - You have T-cell ALL (a different subtype) - You have Down syndrome with ALL - You have had a prior cancer or this is a second leukemia - You have mixed-lineage or undifferentiated leukemia - You have already received chemotherapy, radiation, or immunotherapy for this condition (short-term steroids under 7 days may be acceptable) Talk to your doctor to see if this trial is right for you.